euro adhoc: Intercell AG / Financial Figures/Balance Sheet / Approvals for Japanese Encephalitis vaccine in U.S., Europe and Australia on track for 2008 - All development programs progressing accordin

--------------------------------------------------------------------------------
Disclosure announcement transmitted by euro adhoc. The issuer is responsible
for the content of this announcement.
--------------------------------------------------------------------------------

9-month report

11.11.2008

Intercell successfully advanced parallel regulatory processes in all
key markets for travelers and military personnel - Vaccine against
Japanese Encephalitis expected to obtain market approval in the U.S.,
Europe and Australia in 2008 - U.S. Defense Logistics Agency Request
for Proposal (RFP) for purchase of Japanese Encephalitis (JE) vaccine
for U.S. military in negotiation

» United States: On October 20, the U.S. Food and Drug Administration
(FDA) gave positive feedback on Intercell's application to market its
vaccine against Japanese Encephalitis; Intercell and the agency are
working towards the earliest possible approval - ACIP meeting
discussion on future recommendation of JE vaccine held on October
22/23 with formal decision expected at the February 2009 meeting

» Europe: Approval process advancing according to plan - Intercell
expects a positive opinion from EMEA in December 2008

» Australia: Positive approval decision is expected in December 2008

» Intercell has geared up manufacturing efforts to ensure timely
product delivery to the U.S. military by the end of 2008 and for
commercial product launch in the United States, Europe and
Australia in early 2009

Integration of recent acquisition of IOMAI successfully implemented -
Focus now on aggressively progressing Travelers' Diarrhea patch
vaccine and leveraging patch-based products and technologies

» Strategic focus on late-stage development and industrialization of
the Travelers' Diarrhea patch vaccine and Pandemic Influenza patch
vaccine. In addition, investigation of the use of the patch
technology in new vaccine applications has been effectively
initiated

» Start of pivotal Phase III for Travelers' Diarrhea patch vaccine
expected in H1 2009

» Start of Phase II Pandemic flu vaccine expected in H1 2009

Nosocomial infections - S. aureus vaccine and Pseudomonas vaccine
progressing in clinical programs - All other development programs and
partnerships on track

» Pseudomonas: Start of clinical Phase II/III trials in ventilated
Intensive Care Unit patients expected in December 2008

» S. aureus: Phase II study by Intercell's partner Merck & Co. Inc.
in cardiothoracic surgery progressing well with efficacy data
expected by mid 2009 - further Phase II study initiated in
hemodialysis patients with late- stage kidney disease, expanding
the field of application of the vaccine

» Pneumococcus: After full preparation of clinical strategy, start of
clinical Phase I trials planned for early 2009

Results from 6-month follow-up of Intercell's therapeutic Hepatitis C
vaccine showed statistically significant and long-term antiviral
effect in Phase II patients

» Intercell is currently examining options for future development
including the formulation of the vaccine with IC31® and combination
with other antiviral therapies

Therapeutic Monoclonal Antibodies

» Strategic partnering process initiated to extract maximum value out
of this franchise and to keep internal focus on vaccines

Financial Statements

» Intercell's aggregate revenues doubled from EUR 12.6 m in the 9
months ended September 30, 2007 to EUR 25.3 m in the same period of
2008

» Intercell's net loss decreased by EUR 8.3 m, or 37.6 percent, to
EUR 13.8 m in the first 9 months of 2008 from EUR 22.1 m in the
same period of 2007

» As of September 30, 2008 Intercell had liquid funds of EUR 209.0 m,
of which EUR 49.1 m was cash and EUR 159.9 m was available-for-sale
financial assets

» Cash preservation is the principal goal of Intercell's short-term
cash management strategy. The impact of the current conditions in
the capital markets on the cash portfolio is therefore minimal

KEY FIGURES - FINANCIAL HIGHLIGHTS

EUR in thousands 3 months ended 9 months ended Year ended
Sept 30, Sept 30 Sept 30 Sept 30, Dec 31,
2008 2007 2008 2007 2007

Revenues 7,641 7,375 25,283 12,559 53,349
Net profit/loss (5,140) (6,514) (13,789) (22,085) 5,009
Net operating
profit/loss 24,956 (12,978) (430) (27,480) 41,686

Cash and market-
able securities,
end of period 208,952 218,580 208,952 218,580 284,571

end of announcement euro adhoc
--------------------------------------------------------------------------------

ots Originaltext: Intercell AG
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:

Intercell AG

Lucia Malfent

Head of Communications

Tel. +43 1 20620-1303

lmalfent@intercell.com

Branche: Biotechnology
ISIN: AT0000612601
WKN: A0D8HW
Index: ATX Prime, ATX
Börsen: Wiener Börse AG / official market